Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
  • Current Issue
  • Past Issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • 100th Anniversary of Insulin's Discovery (Jan 2021)
    • Hypoxia-inducible factors in disease pathophysiology and therapeutics (Oct 2020)
    • Latency in Infectious Disease (Jul 2020)
    • Immunotherapy in Hematological Cancers (Apr 2020)
    • Big Data's Future in Medicine (Feb 2020)
    • Mechanisms Underlying the Metabolic Syndrome (Oct 2019)
    • Reparative Immunology (Jul 2019)
    • View all review series ...
  • Viewpoint
  • Collections
    • Recently published
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • Recently published
  • In-Press Preview
  • Commentaries
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
The gut microbiome and metabolic syndrome
Kruttika Dabke, … , Gustaf Hendrick, Suzanne Devkota
Kruttika Dabke, … , Gustaf Hendrick, Suzanne Devkota
Published October 1, 2019
Citation Information: J Clin Invest. 2019;129(10):4050-4057. https://doi.org/10.1172/JCI129194.
View: Text | PDF
Review Series

The gut microbiome and metabolic syndrome

  • Text
  • PDF
Abstract

The metabolic syndrome (MetS) is a constellation of risk factors that, if left untreated, will often progress to greater metabolic defects such as type 2 diabetes and nonalcoholic fatty liver disease. While these risk factors have been established for over 40 years, the definition of MetS warrants reconsideration in light of the substantial data that have emerged from studies of the gut microbiome. In this Review we present the existing recent literature that supports the gut microbiome’s potential influence on the various risk factors of MetS. The interplay of the intestinal microbiota with host metabolism has been shown to be mediated by a myriad of factors, including a defective gut barrier, bile acid metabolism, antibiotic use, and the pleiotropic effects of microbially produced metabolites. These data show that events that start in the gut, often in response to external cues such as diet and circadian disruption, have far-reaching effects beyond the gut.

Authors

Kruttika Dabke, Gustaf Hendrick, Suzanne Devkota

×

Figure 1

A model for the gut microbiome’s interaction with the intestinal epithelial barrier and its contribution to metabolic diseases.

Options: View larger image (or click on image) Download as PowerPoint
A model for the gut microbiome’s interaction with the intestinal epithel...
From the top: High-fat, low-fiber diet induces intestinal dysbiosis, resulting in aberrant metabolite concentrations that disrupt GLP-2–mediated tight junction integrity. This loss of integrity makes the gut epithelium more permissive to microbial lipopolysaccharide (LPS), trimethylamine (TMA), and other metabolites entering the circulation and contributing to the chronic inflammation of liver and adipose tissue that is associated with the development of cardiovascular disease, insulin resistance, and other conditions associated with the metabolic syndrome.
Follow JCI:
Copyright © 2021 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts